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Abstract: Gene electrotransfer is an effective approach for delivering plasmid DNA to a variety of tis-
sues. Delivery of molecules with electric pulses requires control of the electrical parameters to achieve 
effective delivery. Since discomfort or tissue damage may occur with high applied voltage, the reduc-
tion of the applied voltage while achieving the desired expression may be an important improvement. 
One possible approach is to combine electrotransfer with exogenously applied heat. Previous work 
performed in vitro demonstrated that increasing temperature before pulsing can enhance gene expres-
sion and made it possible to reduce electric fields while maintaining expression levels. In the study reported here, this 
combination was evaluated in vivo using a novel electrode device designed with an inserted laser for application of heat. 
The results obtained in this study demonstrated that increased temperature during electrotransfer increased expression or 
maintained expression with a reduction in applied voltage. With further optimization this approach may provide the basis 
for both a novel method and a novel instrument that may greatly enhance translation of gene electrotransfer. 
Keywords: Gene electrotransfer, Skin, Gene therapy, Heat, Electroporation. 
1. INTRODUCTION 
A critical aspect for gene therapy is appropriate delivery. 
Non-viral delivery has a favorable safety profile; however, 
expression levels are typically low without the addition of 
physical, chemical or viral delivery methods. Physical ap-
proaches, including ultrasound, hydrodynamic pressure, and 
electrotransfer, enhance delivery to a variety of tissues and 
are increasingly evaluated for therapeutic applications [1-7]. 
Gene electrotransfer (GET; electroporation) uses electric 
pulses to transiently permeabilize cell membranes allowing 
entry of extracellular nucleic acids into the cell. The current 
challenge is to develop protocols that result in appropriate 
transfection efficiency without adverse effects [8, 9]. 
Skin is an excellent target for gene therapy [10-15] due to 
its easy accessibility for delivery and monitoring. GET of 
skin is a simple and direct method for gene therapy and can 
be accomplished in a minimally invasive way. Several ap-
proaches with potential therapeutic or prophylactic applica-
tions have been evaluated including wound healing [16-18], 
ischemia [19-21], infectious disease vaccines [22-25] and 
cancer vaccines and therapies [5, 8, 26]. To date, sixty-eight 
clinical trials are being enrolled, are ongoing, or are com-
pleted using GET (clinicaltrials.gov “electroporation”, “elec-
trotransfer”). Most of these trials are designed to evaluate 
DNA vaccines against infectious agents or cancer or the ef-
fectiveness of cancer immunotherapy [27].  
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For optimal delivery GET electrodes must be designed 
based on the target tissue and/or the desired endpoint analy-
sis, for example secreted protein, antibody production, or cell 
death. Therefore, important focus areas for GET research 
have been electrode development and the identification of 
“ideal” pulsing parameters. A variety of electrodes for  
in vivo use have been developed including needle, caliper, 
plate, and non-penetrating pin electrodes [23, 28, 29]. While 
each electrode type has its advantages and disadvantages, the 
surface electrodes are attractive because they allow for de-
livery of DNA non-invasively. A surface electrode design is 
well-suited for delivery to the skin. However, the skin is also 
well-adapted to serving as a barrier from intrusion. Our lab 
has developed two surface electrodes for gene delivery to the 
skin that provide high levels of transgene expression. The 
first was the 4 plate electrode (4PE) designed with 4 plates at 
90° angles with a stopper to maintain a constant distance 
between electrodes [28].  
This electrode worked well as it provided a fixed distance 
and allowed for directional control of the applied electric 
field in two perpendicular directions without the need for 
moving the electrodes. While an advantage of this design is 
the fixed distance, the treatment of larger areas also required 
an increase in the electrode gap. Since the applied voltage is 
based on the distance between the electrodes, higher voltages 
are required to achieve effective delivery. These voltages 
potentially cause cellular damage or discomfort [28, 30]. To 
minimize cellular damage or discomfort, a multi-electrode 
array (MEA) was designed. This applicator consisted of 16 
flat pin electrodes 2mm apart in a 4X4 array [23, 29, 31]. 
The electrode covered the same tissue area as the 4PE but 
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smaller electrode distances and an increased number of elec-
trodes allowed for enhanced directional control and a reduc-
tion in applied voltage. 
Despite many successes of GET and the development of 
an increasing number of GET-based therapies, further im-
provement is needed, for example by reducing the necessary 
applied voltage and by increasing the ability to control ex-
pression. While GET is generally a non-thermal process, the 
administration of low heat from an exogenous source could 
potentially enhance delivery. Changes in both skin and core 
body temperature have been demonstrated to affect vasodila-
tion and constriction. Additionally, local warming of tissue 
increases vasodilation, reaching a maximum blood flow in 
the skin at 42°C. This effect is maintained for up to one hour 
after heating [32-34]. The use of heat to enhance delivery is 
based on the hypothesis that permeability of cell membranes 
can be affected by temperature [35]. For example, hyper-
thermia has been used to enhance delivery of chemothera-
peutics [36-39]. Increased temperature can influence the ef-
ficiency of electrotransfer while decreasing the temperature 
to 4
o
C reduces delivery [35]. 
The goal of the current study was to determine if thermal 
assisted gene electrotransfer (TAGET) could enhance trans-
gene expression and/or allow for a reduction of applied volt-
ages in vivo. We hypothesized that moderate heating prior to 
GET in vivo would allow the use of lower applied voltages 
while maintaining gene expression without adverse effects 
on the tissue.  
2. MATERIALS AND METHODS 
2.1. Animals 
Animals used for this study were 6-8 weeks old Female 
Hartley guinea pigs weighing approximately 200-250g. The 
animals were housed at the Old Dominion University animal 
facility and procedures approved by the Old Dominion Insti-
tutional Animal Care and Use Committee.  
2.2. Plasmids 
Endotoxin free preparations at 2mg/ml in physiological 
saline of gWizLuc,encoding firefly luciferase and gWizGFP 
green fluorescence protein (GFP) were purchased (Aldevron, 
Fargo, ND) in this study. Plasmids were prepared endotoxin 
free by Aldevron (proprietary fermentation technology and 
DNA purification) and suspended at 2mg/ml in physiological 
saline.  
2.3. Heat Application 
Animals were anesthetized with O2 containing 2.5-3.0% 
isoflurane. Both left and right flanks were shaved using 
Wahl Shears and extraneous hair removed by cleansing with 
water. To determine the intradermal skin temperature from 
exogenous heating, an 18G needle was inserted intrader-
mally into the left or right flank then replaced with a thermo-
couple temperature probe (Omega, Stamford, CT, USA). 
Baseline tissue temperature readings were recorded. Tem-
perature measurements during heat application and GET 
were collected by positioning the electrode array on the 
skin above the temperature probe. Exogenous laser heat 
was applied at 1, 2 or 3 amps and temperature measured in 
real time. 
2.4. Electrode Design 
Electric pulses were administered utilizing a specially 
constructed applicator. The electric pulse delivery system 
had an integrated infrared radiation emitter Fig. (1) to heat 
the tissue radiatively. The emitter consisted of an optical 
fiber centered between 4 pins with rounded ends spaced 5 
mm apart that acted as electrodes. The optical fiber has ad-
vantages over other nonionizing radiation emitters: its small 
diameter (< 1 mm) and dielectric material can be easily inte-
grated into an existing electrical pulse delivery system. The 
fiber was connected to an infrared semiconductor laser 
which provided up to 8W of radiative power at a wavelength 
of approximately 1m. Adjusting the distance of the fiber to 
the tissue irradiated a well-defined circular area of the tissue.  
2.5. Gene Delivery 
Injection sites were marked to ensure accuracy of data 
collection. Gene delivery and TAGET were assessed after 
intradermal injections of 50 l of plasmid to multiple sites on 
both left and right flanks. The electrode array was positioned 
over the injection area with or without exogenous heating. 
The heat was applied as determined in the first round of ex-
periments at 1 amp for 30 seconds. The tissue remained at 
43°C for approximately 10 seconds, allowing adequate time 
for pulsing at a range of voltages from 50-125V for lu-
ciferase experiments and 50-100V for GFP experiments. 
Based on our previously published results with a similar 
electrode, pulse number, time between pulses and pulse 
length were maintained at 8 pulses, 150ms, and 150ms, re-
spectively [23, 29, 31].  
During the course of these experiments we evaluated  
laser amperage, duration of thermal assistance and applied 
voltage. Gene expression levels were measured for all condi-
tions by in vivo bioluminescent imaging or fluorescent imag-
ing. Visual assessment of the skin was used to determine the 
extent of external tissue damage from the addition of moder-
ate heat.  
2.6. In Vivo Bioluminescent Imaging 
On days 1, 2, 5, 7, 10, and 14, animals were anesthetized 
with O2 containing 2.5-3.0% isoflurane followed by injec-
tions of 50 l of 15 mg/ml D-luciferin (Gold Biotechnology, 
St. Louis, MO) at the plasmid injection sites. The animals 
were confined in an anesthesia chamber for two minutes then 
transferred to the IVIS
®
 Spectrum (Perkin Elmer, Akron, 
OH), imaging chamber under constant anesthesia (O2 con-
taining 2.5% isoflurane). Regions of interest (ROI) were 
selected on the image to encompass the entirety of each in-
jection site independently and compared to untreated control 
ROIs. After background correction bioluminescence results 
were represented as average total flux, photons/sec (p/s).  
2.7. GFP Expression and Analysis 
Forty-eight hours after plasmid delivery, the animals 
were euthanized and the treated areas were excised, fixed in 
4% paraformaldehyde for 1-2 hours, equilibrated in optimum 
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cutting temperature (OCT) compound, snap frozen using dry 
ice and stored at -80°C. Samples were sectioned on a cry-
ostat and mounted in Vectashield
®
 mounting media with 4', 
6-diamidino-2-phenylindole (DAPI; Vector Labs, Burlingame, 
CA) was used for nuclear staining. Slides were imaged on an 
Olympus BX51 fluorescence microscope. The analysis of the 
tissues was performed in a blinded fashion. Two members of 
the research team performed the evaluation independently 
without knowledge of the specific treatment protocol for the 
sample being evaluated. 
2.8. Statistical Analysis 
Temperature and luciferase measurements are repre-
sented as the mean ± SD. Comparisons between specific 
voltage with or without the addition of thermal component 
were performed by Student T-Test. Significance was as-
sumed at p<0.05.  
3. RESULTS AND DISCUSSION 
3.1. Electrode Design, Development and Temperature 
Determination 
An in vivo surface array was designed that incorporated 
features from both the 4PE and MEA [23, 28-31]. This new 
array consisted of four electrodes with 5mm length and 5mm 
gap. Centered within the array was an infrared laser which 
sat flush to the electrode handle and applied a focused beam 
of light to the skin (Fig. 1). The electric pulses were adminis-
tered in 2 sets of four pulses orthogonally. As shown in the 
schematic (Fig. 2), the pulses were administered simultane-
ously from the electrodes for four pulses (i.e., from 1 and 4 
to 2 and 3) then using a manual switch the direction was ro-
tated 90° and pulses administered for four additional pulses 
(1 and 2 to 4 and 3). Fig. (2) provides the full final protocol 
for administration of TAGET (not to scale). The total time 
required for 1 treatment was approximately 45 seconds.  
In a previous in vitro study we evaluated the use of low 
and moderate heat conditions prior to application of GET to 
increase gene expression and determine if reduction in abso-
lute voltage could achieve a reduction in cell mortality [40]. 
This study demonstrated that the application of moderate 
levels of heat could achieve increased gene expression, al-
though utilizing maximal electric fields came at the expense 
of cell viability. Interestingly, we found that when moderate 
exogenous heat was applied prior to pulsing, similar gene 
expression levels could be achieved using about 30% lower 
electric fields. These increased gene expression levels were 
obtained with a significantly higher level of cell viability. An 
important observation from this work was that temperatures 
higher than 43°C resulted in increased cell death [40] while 
lower temperatures did not produce consistently higher gene 
expression. Therefore, 43°C was used for all in vivo experi-
ments.  
The first set of experiments was designed to determine 
the time it took to heat the tissue to 43
o
C. Using a tempera-
ture probe inserted laterally into the dermis of the guinea pig, 
the time to reach 43°C was measured from application of 
direct currents between 1 and 3 amps. Averages of 29 (+/-4), 
23 (+/-7), and 17 (+/-2) seconds were measured for 1, 2, and 
3 amps respectively (Fig. 3A). However, at both 2 and 3 
amps the temperatures continued to rise quickly beyond 
43°C. A consistent rise in heating was obtained by using 1 
amp for 30 seconds. In addition, the temperature probe was 
left inserted in the skin after heating and application of 
TAGET to determine the increase in temperature at the end 
of delivery. Consistent with the previously published in vitro 
results and reports on the lack of heat generation from re-
versible electroporation, changes in temperature were less 
than 1°C. However, minimal visual damage that typically 
healed within 2-4 days was noted at the location of electrode 
contact (Fig. 3B, C). 
3.2. Evaluation of In Vivo Luciferase Gene Expression 
After TAGET 
Luciferase expression was measured to determine 
whether the addition of heat prior to GET would enhance 
expression in vivo over time. Injection of DNA only, ther-
mally assisted injection of DNA, and GET were included as 
controls in these experiments. Guinea pigs received an in-
tradermal injection of 50 l gWizLuc on Day 0 immediately 
 
Fig. (1). TAGET Device. Schematic of an optical fiber that was connected to an infrared laser and inserted into the device. The fiber is situ-
ated centrally between 4 electrodes. The fiber is also placed 1 cm above a 3 mm opening. This gap and opening allows for an increased spot 
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followed by TAGET consisting of 30 seconds of heating at 1 
amp at an applied voltage of 125V, 8 pulses for 150ms.  
Luciferin was injected into the same location as treatment on 
Days 1, 2, 7, and 14 and photon emissions measured on the 
IVIS Spectrum. No differences between the application of 
DNA + heat as compared to DNA alone were observed and 
as expected both had lower expression than DNA + GET 
(Fig. 4). Interestingly the greatest differences between 
TAGET and GET were noted at Day 2 (a 12 fold increase). 
On Day 7, the greatest difference (6-8000 fold) observed was 
between TAGET and DNA injection. At Day 14 TAGET 
groups decreased below the levels of GET. 
While the addition of heat alone did not result in  
enhanced gene expression as compared to injection of DNA 
alone, the combination of heat pretreatment and GET did 
result in higher gene expression at specific time points. 
Therefore, we sought to determine the most appropriate GET 
voltage condition for enhancing gene expression with  
thermal assistance. The previous heating conditions were 
maintained, but the applied voltage varied from 50 to 125V 
(Fig. 5A). The highest gene expression was achieved at an 
applied voltage of 100V with or without the addition of heat. 
However, the addition of heat at 50V resulted in significantly 
(p<0.05) increased gene expression as compared to GET 
alone at Days 6 and 7 (Fig. 5B). Significant (p<0.05) gene 
expression increases were also noted at the same time points 
for 100V. TAGET at lower voltages resulted in similar gene 
expression levels as higher voltage GET conditions. For  
example expression levels achieved with TAGET at 50V 
were similar to levels following 100V GET (Fig. 5B).  
3.3. Location of Gene Expression by TAGET 
A disadvantage of surface electrodes is their inability to 
penetrate deep into the tissue without using high potentially 
damaging electric fields. The addition of heat prior to GET 
might facilitate delivery and might produce gene expression 
deeper within the tissue. To analyze this, gWizGFP plasmid 
was injected and the site treated with and without heat and 
with and without GET at 50 and 100V. After 48 hours, in-
creased GFP protein expression was observed in TAGET 
groups (Fig. 6); however, deeper penetration into the dermis 
was not observed. As with GET, the use of TAGET appears 
to localize expression within the epidermis. 
 
 
Fig. (3). Thermal Application Timing and Effect on Skin. (A) 
Comparison of various laser amperages and the time necessary to 
increase intradermal skin temperature to 43°C. Error is represented 
as standard deviation (SD). (B) Evaluation of tissue damage by 
visual analysis after application of heat and prior to pulsing. (C) 
Evaluation of tissue damage by visual analysis after application of 
heat and after pulsing. 
 
Fig. (2). Experimental Setup and Delivery Protocol. Upper panel: The pulse sequence is outlined. All 4 electrodes are active for each pulse, 
but are applied in two perpendicular directions in sequence. Four pulses in one direction followed by four in a perpendicular direction. Lower 
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Fig. (4). Gene Expression Resulting from TAGET. Luciferase gene 
expression was evaluated during a 2 week time course following 
delivery with or without heat pretreatment and GET. 8 pulses of 
150ms were administered with an applied voltage of 125 with heat 
(HE) or without heat (ET). This was compared to injection of plas-
mid DNA with heat (IO + H) or without heat (IO). Error is repre-
sented as SD. 
CONCLUSION 
In this study, we demonstrated a novel method of in vivo 
GET employing exogenous heat. The intradermal skin tem-
perature was increased to 43°C using an infrared laser and 
electrical fields applied via electrodes. We previously dem-
onstrated that the addition of exogenous heat to GET in vitro 
resulted in maximal gene expression with a reduction of ap-
plied voltage by 30% and an increase in cell viability [40]. 
This current study demonstrated that in vivo TAGET main-
tained gene expression levels while utilizing 50% lower ap-
plied voltage with only short-term adverse effects to the tis-
sue. In addition to gene expression, our current study also 
demonstrated that TAGET did not result in temperature in-
creases above those induced by the exogenous heating 
source.  
We did not demonstrate an increased depth of penetration 
for gene delivery. However, there were several parameters 
which were not evaluated. Throughout the current experi-
mental design the heat level and duration at 43
o
C and pulse 
number, length, and interval were maintained. In the future, 
these parameters could be adjusted to assess the effect of 
their changes. GET parameters can be designed to increase 
penetration by changing electrode distance or electric field 
[28, 29]. The current electrode design could be adjusted to 
evaluate the combination of these factors by reducing the 
electrode distance or increasing the field.  
While this method still requires optimization, the initial 
results suggest that TAGET could prove to be a valuable tool 
for obtaining better control over delivery and subsequent 
protein expression. In addition, to the overall reduction of 
applied voltage, targeted application of heat could aid in lo-
calization of plasmid expression. Future studies will evaluate 
alternate electrode designs, heat application and electrical 
parameters with the goal of optimizing the applications of  







Fig. (5). Comparison of Various Applied Voltages with or without 
Heat Pretreatment. Luciferase gene expression was evaluated with 
GET administered at various applied voltages. Baseline values of 
IO and HIO were also determined. (A) Applied voltages were ad-
ministered from 50-125 with (HE) or without (ET) heat pretreat-
ment. (B) Enlarged graph highlighting differences at 50 and 100 
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